ATP7A and Menkes disease: Currently, no FDA-approved treatment for Menkes disease exists, and clinical studies with Cu-histidine (Cu-His) treatment (1) have shown limited efficacy, with outcomes dependent on residual ATP7A activity and the timing of administration (2).